Exploring Cutting-Edge Strategies for the Management of Triple-Negative Breast Cancer Through Drug Repurposing.

IF 3.3 4区 医学 Q3 CHEMISTRY, MEDICINAL
Sandhya Chaudhary, Kalpana Rahate, Ritam Mondal, Rahul Kumar
{"title":"Exploring Cutting-Edge Strategies for the Management of Triple-Negative Breast Cancer Through Drug Repurposing.","authors":"Sandhya Chaudhary, Kalpana Rahate, Ritam Mondal, Rahul Kumar","doi":"10.2174/0115680266360882250702093727","DOIUrl":null,"url":null,"abstract":"<p><p>Triple-negative breast cancer (TNBC) is the most lethal kind of illness, causing the cancer to spread to other regions of the body and eventually resulting in death. The lack of licensed, targeted drugs that can completely eliminate TNBC is a challenge to the present level of therapeutic options. Developing novel uses for already-approved drugs expedites the lengthy and expensive process of creating new ones. Drug repositioning has been made possible by developments in cheminformatics, genomics, and systems biology. Here we provide what is presumably the first thorough taxonomy of approaches to in silico drug repurposing, classifying them into four categories: structure-based, data-mining-based, transcription signature-based, and physiological networksbased. The most relevant studies from preclinical and clinical contexts are highlighted in this review, which focusses on molecular processes and signalling pathways such as adrenergic receptor, androgen receptor, STAT3, nitric oxide (NO) synthase, or AXL. Its main objective is to repurpose existing medications for the treatment of TNBC. We also focus on repurposing and modifying medications that particularly target this cell type in order to combat metastases and recurrence linked to TNBC. The reason for this is that CSCs are very important and may play a major role in tumour aggressiveness and unfavourable clinical outcomes.</p>","PeriodicalId":11076,"journal":{"name":"Current topics in medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current topics in medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680266360882250702093727","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Triple-negative breast cancer (TNBC) is the most lethal kind of illness, causing the cancer to spread to other regions of the body and eventually resulting in death. The lack of licensed, targeted drugs that can completely eliminate TNBC is a challenge to the present level of therapeutic options. Developing novel uses for already-approved drugs expedites the lengthy and expensive process of creating new ones. Drug repositioning has been made possible by developments in cheminformatics, genomics, and systems biology. Here we provide what is presumably the first thorough taxonomy of approaches to in silico drug repurposing, classifying them into four categories: structure-based, data-mining-based, transcription signature-based, and physiological networksbased. The most relevant studies from preclinical and clinical contexts are highlighted in this review, which focusses on molecular processes and signalling pathways such as adrenergic receptor, androgen receptor, STAT3, nitric oxide (NO) synthase, or AXL. Its main objective is to repurpose existing medications for the treatment of TNBC. We also focus on repurposing and modifying medications that particularly target this cell type in order to combat metastases and recurrence linked to TNBC. The reason for this is that CSCs are very important and may play a major role in tumour aggressiveness and unfavourable clinical outcomes.

通过药物再利用探索三阴性乳腺癌管理的前沿策略。
三阴性乳腺癌(TNBC)是最致命的一种疾病,会导致癌症扩散到身体的其他部位,最终导致死亡。缺乏能够完全消除TNBC的获批靶向药物对目前的治疗选择水平是一个挑战。为已经批准的药物开发新用途,加快了开发新药物的漫长而昂贵的过程。化学信息学、基因组学和系统生物学的发展使药物重新定位成为可能。在这里,我们提供了可能是第一个彻底的计算机药物再利用方法分类,将它们分为四类:基于结构的,基于数据挖掘的,基于转录特征的,以及基于生理网络的。本文综述了临床前和临床背景下最相关的研究,重点介绍了分子过程和信号通路,如肾上腺素能受体、雄激素受体、STAT3、一氧化氮合成酶或AXL。其主要目的是重新利用现有药物治疗TNBC。我们还专注于重新定位和修改药物,特别是针对这种细胞类型,以对抗与TNBC相关的转移和复发。原因是csc非常重要,可能在肿瘤侵袭性和不利的临床结果中起主要作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.40
自引率
2.90%
发文量
186
审稿时长
3-8 weeks
期刊介绍: Current Topics in Medicinal Chemistry is a forum for the review of areas of keen and topical interest to medicinal chemists and others in the allied disciplines. Each issue is solely devoted to a specific topic, containing six to nine reviews, which provide the reader a comprehensive survey of that area. A Guest Editor who is an expert in the topic under review, will assemble each issue. The scope of Current Topics in Medicinal Chemistry will cover all areas of medicinal chemistry, including current developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, compound diversity measurements, drug absorption, drug distribution, metabolism, new and emerging drug targets, natural products, pharmacogenomics, and structure-activity relationships. Medicinal chemistry is a rapidly maturing discipline. The study of how structure and function are related is absolutely essential to understanding the molecular basis of life. Current Topics in Medicinal Chemistry aims to contribute to the growth of scientific knowledge and insight, and facilitate the discovery and development of new therapeutic agents to treat debilitating human disorders. The journal is essential for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important advances.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信